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Calcium channel blockers are drugs that bind to the a, subumt of L-type calcmm channels and selectively inhabit ion movements through these 
channels. Determinatton of the mechanism of channel blockade requires localizatton of drug-binding sues within the primary structure of the 
receptor. In thts study the 1,4-dihydropyridine-binding site of the membrane bound receptor has been identtfied. The covalently labeled receptor 
was purified and digested with trypsin. The labeled peptide fragments were immunoprecipitated with sequence-directed antibodies. The data indicate 
the existence of at least three distmct dihydropyridme-binding domains within the primary structure of the a, subunit. 
Calcium channel blocker: 1,4-Dihydropyridine receptor 
1. INTRODUCTION 
L-Type calcium channels are complex oligomeric 
membrane proteins that regulate voltage-dependent in- 
flux of calcium into excitable cells [1,2], and are one of 
the key components of the excitation contraction cou- 
pling machinery [3]. These channels are also the recep- 
tors for the calcium antagonists or calcium channel 
blockers [4]. These drugs play an important role in the 
treatment of many different cardiovascular disorders, 
particularly hypertension and angina pectoris [5]. All 
calcium channel blockers, in spite of their different 
chemical structures, specifically bind to the a, subunit 
of the L-type calcium channels [6-81 and prevent cal- 
cium influx into the cells, The 1,4_dihydropyridines 
(DHPs) are one of the chemical groups of calcium chan- 
nel blockers [5]. 
Electrophysiological studies have indicated that 
DHPs act on calcium channels only when they are ap- 
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plied to the extracellular compartment [9.10]. These 
data suggest that the DHP-binding site(s) is either lo- 
cated at the extracellular portion of the CI subunit or is 
accessible only from the outside of the cell. 
In the first major attempt to identify the DHP-bind- 
ing site, the strategy involved covalent labeling of the 
solubilized and partially purified ~1, subunit with either 
[3H]azidopine or [3H]nitrendipine, digestion of the re- 
ceptor with proteases, purification and sequencing of 
the labeled peptide fragments [ll]. The amino acid se- 
quences of the purified and labeled peptides corre- 
sponded to amino acid sequences located between 
amino acid residues 1,390-1,437; 13-18 and 712-722 in 
the deduced skeletal muscle L-type calcium channel CI, 
subunit sequence [12]. It was suggested that the DHP- 
binding site was located distal to the S6 transmembrane 
segment of repeat IV at the cytosolic region of the CI, 
subunit, close to a putative cytosolic calcium-binding 
site (EF hand) and at intracellular segments of repeat 
I, close to the cytosolic amino-terminus [l 11. In contrast 
to this, and in agreement with recent electrophysiologi- 
cal studies [9,10], immunoprecipitation of labeled recep- 
tor fragments with sequence-directed antibodies re- 
sulted in a different conclusion [13-151. After labeling 
of partially purified receptors with [3H]diazipine, 
[‘Hlazidopine or [3H]PN200-1 10, two putative extracel- 
lular peptide fragments located adjacent to transmem- 
brane segments S6 of repeats III and IV were identified. 
It was suggested that both of these drug-binding do- 
mains are involved in the DHP-binding site of L-type 
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calcium channels [15]. While the methods of identifica- 
tion of covalently labeled peptide fragments were differ- 
ent, all previous studies utilized solubilized and partially 
purified receptor protein, which has approximately an 
order of magnitude lower affinity for DHPs than mem- 
brane-bound receptors [6]. 
In this study the receptors were photoaffinity labeled 
in their native. membrane-bound and high-affinity 
form. After these receptors were purified and digested 
with trypsin, three distinct covalently labeled DHP- 
binding domains were identified with sequence-directed 
antibodies. 
2. MATERIALS AND METHODS 
2.1. Prepuralwn of skeletnl muKle memhrcmeJ 
Membranes enriched in transverse tubules were Isolated from fresh 
rabbit skeletal muscle accordmg to Glossmann and Ferry [16]. The 
density of DHP-binding sites m membranes was determined by radl- 
ohgand-bmdmg assay as previously described [4]. These membranes 
had a maxlmum bmdmg capacity (B,,,,,) of 5-15 pmol/mg protem and 
a K,, of 0.3-0.5 nM for (+)[‘H]PNXO~l 10. 
2 2. Photouffinrtv bhrlmg und .whrhd~=~rtzon of the n,enlhvcme-boutlti , 
rrcrptor., 
Membranes (600 mg) were diluted to a protein concentration of 10 
mg/ml with a labeling buffer (50 mM Tris-HCI. pH 7.4, at 24°C 
contaimng the following protease mhlbitors: 0.25 mM PMSF, 1 mM 
IAA. 1 PM leupeptin and 1 PM pepstatm). The membrane suspension 
was homogenized in a Thomas C Size homogenizer and centrifuged 
at 100,000 x g for 40 mm. The pellet was resuspended m the labehng 
buffer to obtain a 10 mg/ml protein concentration. This suspension 
was Incubated at 24°C with 2 nM [‘Hlazldopine (specific activity 50 
Cl/mmol, Amersham Int.). Non-specific labeling was measured m a 
sample that also contained 2 PM unlabeled racemlc PN200-I IO. At 
the end of the incubation. the samples were placed on Ice and irradl- 
ated with a Philips 38WITL UV lamp from a &stance of 10 cm for 15 
mm The Irradiated samples were centrifuged at 100.000 x g for 40 
mm. The pellet was diluted with a solubihzation buffer that contamed 
1% dlgitonin. 10 mM HEPES-Tns. pH 7.4. at 4°C. 185 mM KCl. 1.5 
mM CaCI,, 0.25 mM PMSF, 1 mM IAA, 1 PM leupeptin and 1 PM 
pepstatm and incubated on ice for 60 min. The insoluble materials 
were removed by centrifugation at 100,000 x g for 50 mm. The super- 
natant-contaming solublhzed membrane proteins was used m subse- 
quent studies. 
2.3. A’heat germ lectm ufjnrty chromutogrupll> 
The solubilized proteins were Incubated for 3 h at 4°C ~lth 25 ml 
of WGL-Sepharose 6MB (Pharmacia Fine Chemicals. Uppsala, Swe- 
den) that had previously been equilibrated with the solubihzatlon 
buffer. The WGL-Sepharose 6MB was packed into a 1.5 cm x 30 cm 
column, washed with 50 ml solubihzatlon buffer and then with 700 ml 
of solubihzatlon buffer contaming a reduced concentration (0 1%) of 
digitonin. .V-Acetylglucosamme (400 mM) dissolved m this buffer was 
used to elute glycoproteins from the column Fractions were collected 
and the elution of labeled proteins was monitored by measuring the 
radIoactIvIty m 50 ~1 aliquots taken from each fraction. The fractions 
containing the highest radloactivlty were combined, lyophihzed and 
retained for subsequent experiments 
2.4. PurIficatwn oJ the f~H]a_idopme-lubeie~l CL, subumt 
Partially purified and lyophllized proteins were dissolved m distilled 
water and reduced with 1% 2-mercaptoethanol for 15 min at 24°C 
before carboxymethylation with iodoacetamlde for 1 h at 24°C The 
photoaffimty-labeled a, subunit was then further purified by size ex- 
clusion chromatography on tandemly connected TSKgel G columns 
(Tosoh Corp., Japan: TSKgel SW guard column. 75 x 7.5 mm ID, 
TSKgel G3000SW column, 600 x 7.5 mm ID: and TSKgel G4000SW 
column, 600 x 7.5 mm ID) m 20 mM sodium phosphate buffer, pH 
7. containing 0.2% sodium dodecylsulfate at a flow rate of 0 5 ml/mm. 
1 ml fractions were collected and the radloactlvlty was measured m 
50 ~1 ahquots taken from each fraction. The peak fractions were 
combined, lyoplnhzed and stored at -70°C. Samples of the combmed 
fractions were subjected to SDS-PAGE using 5 - 15% polyacrylamide 
gradient gels. The gels were stained with Coomassie blue. The radioac- 
tivity was determined in gel slices according to the method of Su- 
nahara et al. [17]. 
2.5. Genertrllon of proteolytlc fragments of‘ purrfied (‘H]a:idopmr- 
lubeled a, subunrt 
The purified [ZH]azidopine-labeled a, subunit preparation contam- 
ing approximately 8 x lo5 dpm was dissolved m distilled water by 
ultrasonicatlon. The soluble protein was first dialyzed against 6 M 
urea and then against distilled water before lyophihzatlon. The con- 
centrated sample was digested with trypsm (50,&m]) for 13 hat 37°C 
in 0.1 M Trls-HCI buffer. pH 8.0, containing 2 mM CaC12. The reac- 
tion was terminated by the addition of diisopropyl phosphofluoridate 
to a final concentration of 5 mM [13]. 
2.6 Immunoprecip~tatron of cowlent!v lubeled receptor fragments b? 
.tequence-drrectrd antibodies 
Sequence-directed polyclonal antibodies were generated as previ- 
ously described [I 31. AntibodIes PO, PI, P7 and PlO were raised against 
synthetic peptides correspondmg to ammo acid residues 1.401-1.414 
n PI0 n 
Fig. 
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Location of amino acid sequences in a membrane-foldmg model of the skeletal muscle L-type calcium channel a, subunit which were selected 
for generation of sequence-directed antibodies PO, PI. P5, P7 and PlO. 
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(PO), 1.33%1,351 (Pl), 1,011&1,026 (P7) and 264280 (PlO) in the 
deduced amino acid sequence of the skeletal muscle a, subunit [12]. 
Antibody P5 was raised against a synthetic peptide corresponding to 
amino acid residues 1,69 l-l.701 of the cardiac L-type calcium channel 
a, subunit [18]. This sequence is highly homologous to amino acid 
residues 1.56661.582 in the skeletal muscle u, subunit [12]. The loca- 
tion of amino acid sequences within the primary structure of the 
skeletal muscle L-type calcium channel a, subumt is illustrated m 
Fig. 1. 
The antibodies were bound to protein A-Sepharose 4B by incubat- 
mg 1 vol. of serum with 1 vol. of swollen gel in RIA buffer (10 mM 
Tris-HCl, pH 7.2, 150 mM NaCl. 0.1% Triton X-100) for 2 h at 4°C. 
After washing the gel with ice-cold RIA buffer. tryptic fragments of 
the receptor were added. The peptide fragments were incubated with 
the antibodies for 2 hours at room temperature and the gel was washed 
with RIA buffer. Immunoprecipitated radioactivity was determined 
by SDS-PAGE after denaturdtion of the resin m SDS sample buffer 
and counting radioactivity in gel slices. 
3. RESULTS 
3.1. PhotoajJnity labeling of the membrane-bound re- 
ceptors with [3H]acidopine 
Skeletal muscle membranes enriched in DHP recep- 
tors were incubated with [3H]azidopine at a receptor-to- 
ligand ratio of 5O:l. After equilibrium binding was 
achieved (60 min), photoincorporation of t3H]azidopine 
was induced by UV irradiation. The free ligand, except 
the one entrapped in the pellet, was removed by centrif- 
ugation. The free ligand in the pellet was diluted and 
gradually removed by solubilization and the subsequent 
chromatographic steps. 
3.2. Purzjication of the labeled a, subunit 
The photoaffinity-labeled a, subunit was first puri- 
fied by wheat germ lectin affinity chromatography. In- 
corporation of [3H]azidopine into the partially purified 
a, subunit was verified by SDS-PAGE, gel slicing and 
by counting radioactivity in the gel slices (data not 
shown). These partially purified receptors were carbox- 
ymethylated and solubilized with SDS before final puri- 
fication by high performance liquid chromatography 
using size exclusion columns. The size exclusion chrom- 
atography of the solubilized and denatured receptors 
resulted in three radioactive peaks. Each peak appeared 
to represent specific labeling (Fig. 2, upper panel). To 
determine which peak contained the a, subunit, the 
peak radioactive fractions from the totally labeled prep- 
aration were pooled and a sample was subjected to 
SDS-PAGE. The radioactivity was counted in gel slices. 
The second and third radioactive peaks that eluted at 
27-30 ml and 37-39 ml from the size exclusion columns 
did not contain intact DHP receptors or other proteins 
detectable with Coomassie blue staining. In these cases 
the radioactivity migrated faster than the dye and eluted 
from the gel (Figure 2, lower panel). On the other hand, 
the first radioactive peak, that was eluted at 20-23 ml 
from the size exclusion columns, did contain the pho- 
toaffinity-labeled, 170 kDa a, subunit (Fig. 2, lower 
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Fig. 2. Identification of intact, [3H]azidopme-labeled a, subunits in 
purified receptor preparations. The radioactivity present in the frac- 
tions collected after injection of totally and non-specifically labeled 
receptors into size exclusion columns is shown m the upper panel. Size 
exclusion chromatography (SEC) fractions 20-22. 27730 and 37-39 
were pooled and aliquots containing 10,000 dpm were subjected to 
SDS-PAGE. The radioactivity present in 3 mm gel slices is illustrated 
in the lower panel. 
panel). These fractions were used either directly or after 
tryptic digestion for immunochemical analysis. 
3.3. Identljication of photoaffinity-labeled peptide frag- 
ments with sequence-directed antibodies 
The purified photoaffinity-labeled a, subunit prepa- 
ration was immunoprecipitated with all sequence-di- 
rected antibodies used in this study (PO, Pl, P5, P7 and 
PlO). In contrast, the photoaffinity-labeled tryptic frag- 
ments of the a, subunit were immunoprecipitated by 
only three of these antibodies, Pl, P7 and PlO (Fig. 3). 
Approximately 60% of specific [3H]azidopine labeling 
was immunoprecipitated with these three antibodies. 
There was no significant amount of radioactivity im- 
munoprecipitated with antibodies PO and P5 or with 
preimmune serum. 
179 
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Fig. 3. Immunoprecipitatlon of [‘Hlazidopme-labeled a, subunit by 
sequence-dlrected antibodIes (PO, Pl, P5, P7 and PIO) before (open 
bars) and after dIgestIon with trypsin (filled bars) PRE, prelmmune 
serum. 
SDS-PAGE analysis of the immunoprecipitated, la- 
beled peptides revealed that anti-P7 and anti-PI anti- 
bodies recognized a 3.5 kDa and a 6.2-7.4 kDa frag- 
ment, respectively, as has previously been shown after 
labeling of the DHP receptor with [‘Hldiazipine [ 131 or 
[3H]azidopine [14]. In addition, anti-PI0 antibody rec- 
ognized a 10 kDa photoaffinity-labeled fragment. The 
location of potential tryptic cleavage sites near the PlO 
sequence suggests that the 10 kDa-labeled tryptic frag- 
ment resulted from cleavage at Arg-262 and Lys-339 of 
the CI, subunit, and represents the transmembrane seg- 
ment S6 of domain I and the adjacent extracellular pep- 
tide loop. 
4. DISCUSSION 
Identification of drug-binding sites within the pri- 
mary structure of the ~1, subunit of the L-type calcium 
channels is necessary for determination of the molecular 
mechanism of action of calcium channel blockers. A 
considerable effort has been made to achieve this goal 
[11,13,14,19]. 
In the present study, the 1.4-dihydropyridine-binding 
domains of the skeletal muscle L-type calcium channels 
were determined after photoaffinity labeling of mem- 
brane-bound receptors. [3H]Azidopine has approxi- 
mately IO-times higher affinity (K,, = 0.3 nM) to mem- 
brane-bound receptors than to partially purified recep- 
tors (K, = 3 nM) [6]. Therefore, the membrane-bound 
receptors required lo-times lower concentration of the 
labeled ligand than the partially purified receptor prep- 
arations for the same fractional occupancy. The possi- 
bility of non-specific labeling was reduced by maintain- 
ing a high (50: 1) ratio between receptor and the labeled 
ligand concentrations. Under such circumstances, the 
non-specific labeling was less than 10% of the total la- 
beling. Furthermore, the non-specifically labeled mem- 
brane components were separated from the labeled re- 
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ceptors during subsequent solubilization and purifica- 
tion steps. 
Identification of labeled peptides by immunoprecipi- 
tation with sequence-directed antibodies has proven to 
be a powerful procedure in determination of drug recep- 
tor sites [13,14,19]. We have successfully used this pro- 
cedure and identified three distinct [3H]azidopine-la- 
beled polypeptides. These are located on peptide loops 
between transmembrane segments S5 and S6 of repeats 
I, III and IV. All three domains are suggested to be at 
the extracellular opening of the channel pore based on 
a transmembrane-folding model of the CT, subunit [15]. 
Two of these DHP 1,4-dihydropyridine-binding do- 
mains have been identified before [13,14] but the third 
one, which is located on repeat I, has not. Therefore, 
our results confirm previous findings suggesting that 
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Fig. 4. IdenMicatlon of [3H]azidopine-labeled tryptlc fragments of the 
a, subunit. Proteolytlc fragments were separated by SDS-PAGE and 
the radIoactIvity (dpm) was determined m 3 mm gel slices. The radio- 
labeled peptldes. (10 kDa. 6 2 kDa and 3 5 kDa) present m the digest 
before (0) and after immunoprecipltatlon with sequence-directed an- 
tlbodies anti-P7 (+ ), anti-PI (0) and antl-P10 (0) are indicated by 
arrows. 
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putative extracellular segments of the a, subunit located 
between transmembrane segments S5 and S6 of repeats 
III and IV, that may fold into the pore of the channel, 
represent-binding domains of the 1,4_dihydropyridine 
receptor [15]. However, our data refine the localization 
by identifying a third putative extracellular segment of 
the cq subunit located between transmembrane seg- 
ments S5 and S6 of repeat I, which we feel participates 
in the formation of the DHP receptor. This ‘peptide 
loop’ may fold into the channel pore together with the 
other DHP-binding loops. Thus, we suggest that the 
DHP receptor consists of at least three distinct binding 
domains located distal from each other in the primary 
structure of the receptor but may be close to each other 
in the three-dimensional structure of the CX, subunit. 
This is not unexpected since the existence of multi-sub- 
site receptors has been postulated for several drugs and 
hormones [20]. 
Our data suggest that the DHP receptor consists of 
at least three distinct drug-binding domains, and that 
1,4_dihydropyridines are multivalent ligands that bind 
to more than one receptor subsite simultaneously and 
may act as reversible cross-linkers of peptide loops [21] 
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